Prevalence, Characteristics and Outcomes of Older Patients with Hereditary Versus Wild-Type Transthyretin Amyloid Cardiomyopathy
Aldostefano Porcari(University of Trieste), Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Helen J. Lachmann(Royal Free London NHS Foundation Trust), Gianfranco Sinagra(University of Trieste), Lucia Venneri(MACOM (United States)), Philip N. Hawkins(The Royal Free Hospital), Janet A. Gilbertson(Children's Cancer and Leukaemia Group), Marianna Fontana(Johnson & Johnson (United States)), Rishi Patel(MACOM (United States)), Ambra Masi(MACOM (United States)), Marco Merlo(Universidade da Coruña), Carol Whelan(Boston University), Ashutosh Wechalekar(Boston University), Yousuf Razvi(MACOM (United States)), Muhammad U. Rauf(MACOM (United States)), Candida Cristina Quarta(Boston University), David F. Hutt(Boston University), Adam Ioannou(MACOM (United States)), Ana Martinez–Naharro(Children's Cancer and Leukaemia Group), Dorota Rowczenio(Children's Cancer and Leukaemia Group)
Cited by 97
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
NALP3 Forms an IL-1β-Processing Inflammasome with Increased Activity in Muckle-Wells Autoinflammatory Disorder
|Immunity|2004|1.7k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k